AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02454218 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The intervention session with tDCS lasts for 20 minutes. tDCS uses rubber electrodes that are within sponges that are moistened with saline. These electrodes are placed on the participant's head. Through these electrodes will pass a weak electrical current that can at most cause mild itching at the site where the electrode is positioned. The generated electric current is equivalent to a small common battery that we use to run toys or radios. The procedure does not require that the patient be subjected to shocks, cuts or surgery.~The participant will receive active tDCS or placebo, but receive both types of intervention during the performance of the two sessions.
Study NCT02454218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The intervention session with tDCS lasts for 20 minutes. tDCS uses rubber electrodes that are within sponges that are moistened with saline. These electrodes are placed on the participant's head. Through these electrodes will pass a weak electrical current that can at most cause mild itching at the site where the electrode is positioned. The generated electric current is equivalent to a small common battery that we use to run toys or radios. The procedure does not require that the patient be subjected to shocks, cuts or surgery.~The participant will receive active tDCS or placebo, but receive both types of intervention during the performance of the two sessions.
Study NCT01836575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed, 500 mg/m2 + Pretreatment \[dexamethasone + vitamin B12 + folic acid, as per pemetrexed label\] + Antiemetic therapy at investigator's discretion.
Study NCT01836575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, 500 mg/m2 + Pretreatment \[dexamethasone + vitamin B12 + folic acid, as per pemetrexed label\] + Antiemetic therapy at investigator's discretion.
Study NCT01836575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin \[Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle\].
Study NCT01126970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat Placebo
Description: Orlistat Placebo t.i.d.
Study NCT01126970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velneperit Placebo
Description: Velneperit Placebo q.d
Study NCT01126970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Velneperit Placebo
Description: Velneperit Placebo q.d
Study NCT01126970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reduced Calorie Diet
Description: Reduced calorie diet
Study NCT01126970 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reduced Calorie Diet
Description: Reduced calorie diet
Study NCT01126970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Calorie Diet
Description: Reduced calorie diet
Study NCT01139489 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: procalcitonin-guidance
Description: If procalcitonin levels decrease to predefined levels, antibiotic therapy will be discontinued.
Study NCT02628470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical manipulation
Description: cervical high-velocity low-amplitude thrust manipulation
Study NCT02628470 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cervical control exercises
Description: Exercises of flexion, extension and rotation of the cervical spine
Study NCT02628470 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oscillatory mobilization technique
Description: Joint mobilization technique type III according Maitland
Study NCT03373292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venous stenting for internal jugular vein stenosis
Description: After confirming the diagnosis of IJVS by Jugular Vein Doppler Ultrasound, Magnetic Resonance Venography (MRV) and/or Computed Tomography Venography (CTV), and excluding external compression-induced stenosis as well as other causes of intracranial pressure elevation, patients will be divided into two groups randomly (30 for each group: group-1 and group-2).~Patients in Group-1 will receive Digital Subtraction Angiography (DSA) immediately after enrollment, and trans-stenotic pressures (∆MPGs) will be measured, balloon angioplasty bridging venous stenting will be performed when their ∆MPGs of jugular veins are equal to or greater than 5.44 cmH₂O (4 mmHg).
Study NCT03373292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-month routine medical treatment followed by venous stenting for internal jugular vein stenosis
Description: Patients in Group-2 will receive routine medical treatment for one month. Afterwards, they will undergo DSA (the procedure is the same as that in Group-1).~Notably, patients in Group-2 with medical uncontrolled intracranial hypertension will be provided stenting of their jugular veins at any time during the one-month routine medical treatment, in attempt to reduce their intracranial pressure and ameliorate visual damages in time.
Study NCT00325273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: use Lactobacillus rhamnosus GG in pregnant women from gestational 26 weeks till newborn 6 months
Study NCT01443078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Study NCT01443078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT01443078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01443078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Study NCT01443078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Study NCT01443078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02998983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racotumomab
Study NCT02027519 — intervention group
Intervention type: OTHER
Intervention: HIV Self-testing with Standard Counseling and Testing (SCT) Confirmation
Description: Partners of the index participants and other household members will be offered HIV self-testing by the mobile testing team. Those who consent to HIV self-testing with SCT confirmation will complete the following procedures:~* Undergo standardized pre-test counseling and demonstration of use of HIV rapid test kit by trained study staff, including how to determine test results~  * Self-administer HIV rapid test and read test results~ * Provide study staff with self-testing result~ * Undergo confirmatory testing as well as post-test counseling by study staff (SCT) if the initial self-test is positive, there is any doubt about the results, or the test reveals couple discordance
Study NCT01497457 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR saline peritoneography
Description: Ultrasound-guided Intraperitoneal injection of 250cc of steril saline solution with a 22G needle, followed by rectal MR imaging
Study NCT02974283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen therapy
Description: In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should within 1 hour after diagnosed ischemic stroke and uninterrupted during other treatments including r-tPA thrombolytic therapy and standard clinical treatment. .~Other Names:
Study NCT01390649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro10
Description: IgPro10 will be administrated by IV infusion either a single dose of 1 g/kg bw on 1 day or 2 doses of 1 g/kg bw on 2 days (2 g/kg bw total dose) dependent on the response to the first treatment.
Study NCT02287012 — intervention group
Intervention type: OTHER
Intervention: Time/Motion evaluation of actual apheresis
Description: The actual apheresis events will be measured in consecutive patients scheduled to be candidates for peripheral blood stem mobilization in the apheresis area of the hospital. Each apheresis will be considered as one event . Should the patient receive more than 1 apheresis, each apheresis will be considered as one different event.
Study NCT04523844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide-brimonidine Fixed Combination
Description: In case group one drop of a fixed combination of brinzolamide-brimonidine will be instilled two hours before the injection
Study NCT03273270 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: transcranial magnetic stimulation
Study NCT03273270 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: transcranial magnetic stimulation
Study NCT01182142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1,250 mg/m2 orally twice a day, days 1-14
Study NCT01626430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gamma delta TRF
Description: 50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
Study NCT01626430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
Study NCT03407625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foley bulb plus Oral Misoprostol
Description: Although labeled experimental for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States.
Study NCT03407625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Misoprostol
Description: Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.
Study NCT00334321 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Study NCT00334321 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intracavitary vaginal brachytherapy
Study NCT00334321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT00334321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT00938236 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporine Inhalation Solution (CIS)
Description: Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration
Study NCT02667990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orthopaedic stilettoe
Description: stilettos with orthopaedic in-sole buildt into the shoe
Study NCT03404232 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynesys DTO device (Zimmer Spine, Inc.)
Description: All patients receive posterior hybrid instrumentation.
Study NCT00270335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT03530969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Efficacy Assessment
Description: Health Care Professional's self-efficacy will be assessed by 12 ratings of self-reported confidence from (1) strongly disagree to (5) strongly agree in module-specific topics both before and after the training.
Study NCT03530969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UCLA Geriatrics Attitudes Scale
Description: The UCLA Geriatrics Attitudes Scale is a 14-item scale developed to assess health care providers' attitudes toward older persons and caring for older patients.
Study NCT03530969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Course Evaluations
Description: The evaluation surveys for each of the three modules will contain fifteen statements assessing post-training attitudes regarding the skills learned and application of skills in oncology clinical practice, measured on a 5-point Likert scale.
Study NCT03530969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Consultation and Relational Empathy (CARE) questionnaire
Description: The Consultation and Relational Empathy (CARE) questionnaire is a 10-item self-report scale that measures a patient's satisfaction with how empathic their health care providers (HCP) was within a specific consultation.
Study NCT03530969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consumer Assessment of Health Care Providers and Systems Program (CAHPS)
Description: Patients perceptions of the quality of their interactions with their clinicians will be rated with 6 items from the Consumer Assessment of Health Care Providers and Systems Program (CAHPS)
Study NCT03530969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient activation measure (PAM) scale
Description: The PAM scale contains 22 items that assess patient engagement in their care process.
Study NCT02605070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bravelle
Description: Bravelle will be provided to all patients in the treatment group by the principal investigator (PI) or another member of the research team.~From week nine on, the patients will undergo a physical examination on three different occasions to assess the appearance of any adverse reactions during treatment. It will be up to the patient to communicate the appearance of signs or symptoms which could be associated with the use of the drug.~At week 12 the patient will be scheduled for another visit to perform a semen study and to measure new hormone levels. To this end, a blood test will be carried out (FSH, LH, estradiol, total testosterone, SHBG, and albumin to calculate the amount of bioavailable testosterone). A semen sample will also be obtained to carry out a spermiogram according to WHO guidelines; part of this sample will be used for epigenetic analysis.
Study NCT04049864 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine
Description: conjugate of plasmid DNA with linear polyethylenimine 20 kDa (PEI) One dose includes 400 µg of DNA and 500 µg of PEI.
Study NCT04049864 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella oral vaccine
Description: suspension 10\^10 CFU of an attenuated Salmonella enterica serovar typhimurium strain (SS2017) containing the plasmid of the corresponding DNA vaccine.
Study NCT04049864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide is prescribed in a dose of 25 mg / day in a course of three weeks starting 7 days before the first vaccination course and ending on the day of the last vaccination course.
Study NCT03823456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-acupressure
Description: We teach participants how to using self-acupressure to manage insomnia, depression, and anxiety. Six acupoints are included in our acupressure protocol which are Baihui, Yintang, Fengchi, Neiguan, Shenmen, and Taichong. Participants are requested to stimulate each acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from Anxiety and Depression Association of American.
Study NCT00493454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 250 mg/m\^2 IV Over 6 to 8 Hours
Study NCT00493454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ^111 In Ibritumomab Tiuxetan
Description: 1.6 mg IV Over 10 Minutes x 1 Day
Study NCT03860207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humanized 3F8 Bispecific Antibody
Description: Phase I Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.Phase II Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.
Study NCT03860207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: In cycle 1, blood is drawn for PK studies.
Study NCT04734834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prodovite® VMP35
Description: Efficacy of Prodovite® VMP35 will be Assessed as Compared to Placebo
Study NCT04734834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prodovite® VMP35
Description: Efficacy of Prodovite® VMP35 will be Assessed as Compared to Placebo
Study NCT04412057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERC-002
Description: Administered once subcutaneously at 16 mg/kg dose up to a maximum dose of 1200 mg.
Study NCT04412057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once subcutaneously
Study NCT04017559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: A pharmacist trained in MI delivered three recorded MI sessions over 2 months, with follow up at 3, 4 and 6 months.
Study NCT03823456 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Self-acupressure
Description: We using a sham acupressure protocol to teach participants in this group. Six sham acupoints are included in the protocol. The sham acupoints are located 2-5cm away from the true acupoints. Participants are requested to stimulate each sham acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from the Anxiety and Depression Association of American.
Study NCT02488668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface Electrical Stimulation
Description: Surface electrical stimulation using the following devices; 1) INOMED surface stimulator, 2) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject.
Study NCT00779402 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen.
Study NCT00779402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Description: Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Study NCT01953094 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Screening Anal Pap Smear - No High Resolution Anoscopy
Study NCT01953094 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Screening Anal Pap Smear - With High Resolution Anoscopy
Study NCT02667990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard stiletto
Description: standard stiletto without insole
Study NCT02667990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comfy trainer
Description: comfy trainer
Study NCT03389061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sofosbuvir/velpatasvir tablet
Description: Single-dose SOF/VEL as a whole tablet in a fasted state.
Study NCT03389061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir/velpatasvir crushed
Description: Single-dose crushed SOF/VEL in a fasted state.
Study NCT02427477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: Subjects will wear the contact lenses in both eyes for seven days
Study NCT02283671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tolerogenic Dendritic cells loaded with myelin peptides
Description: Somatic-cell therapy medicines application
Study NCT03187028 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Only
Description: Diet counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet counseling.
Study NCT03187028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + Exercise
Description: Diet and exercise counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet and exercise counseling.
Study NCT04476745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Dietary Supplement: Vitamin D3 (50,000) IU / week for 8 weeks
Study NCT01544062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: Total of 6 doses of 1,000 mg IV acetaminophen at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
Study NCT01544062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Total of 6 doses of 100 mL of normal saline at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.